Skip to content
OpenCapital
Get started

Marker Therapeutics, Inc. MRKR Q3 2025 earnings

Reported November 13, 2025 · Before market open

Revenue$1.2MBeat by $509.9K
EPS-$0.12Beat by $0.24
Revenue estimate$723.0K
EPS estimate-$0.36

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$682.1K
EPS estimate-$0.25

Versus estimates

Revenue

Q4 2025$1.1MBeat by $417.9K
Q3 2025$1.2MBeat by $509.9K
Q2 2025$861.2KBeat by $430.6KQ1 2025$349.1KBeat by $174.6KQ4 2024$2.3MBeat by $1.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.02Q4 2025-$0.04Beat by $0.17
Q3 2025-$0.12Beat by $0.24
Q2 2025-$0.29Beat by $0.01Q1 2025-$0.27Beat by $0.39Q4 2024-$0.42Miss by $0.20

Ask the moment Marker Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Marker Therapeutics, Inc. report Q3 2025 earnings?
Marker Therapeutics, Inc. (MRKR) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Marker Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Marker Therapeutics, Inc. reported revenue of $1.2M and eps of $-0.12 for Q3 2025.
Did Marker Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $723.0K by $509.9K. EPS beat the consensus estimate of $-0.36 by $0.24.
How did Marker Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 36.0% from $1.9M a year earlier and eps grew 53.8% from $-0.26.
Where can I find Marker Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-111940) and the 10-Q periodic report (0001104659-25-111502) directly on SEC EDGAR. The filing index links above go to sec.gov.